Ex-Press房水引流物植入术治疗新生血管性青光眼临床观察

目的　评价Ex-Press房水引流物植入术治疗新生血管性青光眼的有效性和安全性。方法　2014年5月至2017年6月在北京同仁医院确诊为新生血管性青光眼并行Ex-Press房水引流物植入术的患者23例（23眼）,术后随访12个月,观察术前、术后患者的眼压、降眼压药物种类及术后并发症情况。结果　23例患者术前眼压为（39.0±4.2）mmHg（1 kPa=7.5 mmHg）;术后1个月、3个月、6个月、12个月眼压分别为（12.8±0.7）mmHg、（15.5±0.9）mmHg、（18.4±1.0）mmHg、（20.6±2.5）mmHg,与术前相比差异均有统计学意义（均为P<0.05）。至末次随访时,手术完全成功17眼（73.9%）,条件成功1眼（4.3%）,总手术成功率78.3%。术前使用抗青光眼药物（3.3±0.9）种,术后12个月为（0.2±0.5）种。术后浅前房3眼、前房积血1眼、高眼压7眼。结论　Ex-Press房水引流物植入术安全、有效、并发症少,可作为新生血管性青光眼患者的手术治疗方式之一。     

Visual prognosis, intraocular pressure control and complications in phacomorphic glaucoma following manual small incision cataract surgery

Aims:

To evaluate intraocular pressure (IOP) control, visual prognosis and complications following manual small incision cataract surgery among eyes with phacomorphic glaucoma.

Materials and Methods:

This prospective, non-randomized interventional consecutive case series included all patients with phacomorphic glaucoma who presented to a tertiary eye care referral center in South India between March 2006 and April 2007. All patients underwent slit-lamp bio-microscopy, applanation tonometry and gonioscopy of the other eye to rule out angle closure. Small incision cataract surgery with intraocular lens implantation was performed in all affected eyes. Complete ophthalmic examination was done at each follow-up visit.

Results:

A total of 74 eyes with phacomorphic glaucoma were included in this study. The preoperative mean IOP was 38.4±14.3 mmHg and mean IOP at last follow-up was 12.7±2.4 mmHg. There was a statistically significant difference between IOP at presentation and IOP at last follow-up (P< 0.001). None of the eyes required long-term antiglaucoma medication. No significant intraoperative complications were noted. The final postoperative best corrected visual acuity was 20/40 or better in 51 patients. Eighteen eyes had corneal edema and 36 eyes had anterior chamber inflammation. Both conditions resolved with standard medical therapy.

Conclusion:

Manual small incision cataract surgery is safe and effective in controlling IOP and achieving good functional visual acuity with minimal complications in the management of phacomorphic glaucoma in developing countries.     

康柏西普联合Ahmed引流阀植入及白内障超声乳化贯序治疗新生血管性青光眼

目的：评估玻璃体腔注射康柏西普联合Ahmed引流阀植入及白内障超声乳化吸除贯序治疗新生血管性青光眼(NVG)的疗效。

方法：回顾性分析。纳入2018-06/2020-01我院眼科收治合并白内障的NVG患者18例18眼。所有患者均术前3～7d行玻璃体腔注射康柏西普,符合手术指征后进行白内障超声乳化吸除术联合Ahmed引流阀植入术,术后随访12mo,记录最佳矫正视力(BCVA)、眼压、虹膜新生血管消退情况、手术效果及并发症情况。

结果：术后1、7d,1、3、6mo,1a眼压分别为25.94±11.82、15.39±4.97、15.94±2.69、15.33±4.54、18.89±7.95和16.27±5.22mmHg,均低于术前平均眼压51.44±8.18mmHg(P<0.05)。末次随访时67%(12/18)患者BCVA提高,28%(5/18)BCVA不变,1眼BCVA降低; 术后1a手术完全成功15眼(83%),部分成功2眼(11%),失败1眼(6%)。

结论：玻璃体腔注射康柏西普联合Ahmed引流阀植入及白内障超声乳化吸除贯序治疗合并白内障的NVG可以有效控制术后眼压,同时尽可能地提高患者BCVA,便于随诊和治疗视网膜原发疾病,可作为合并白内障的NVG治疗的有效方法。     

Effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve implantation: a randomized control trial

Importance

The effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve (AGV) implantation.

Background

Evaluation of efficacy and safety of subconjunctival Bevacizumab injection adjunctive to AGV implantation.

Design

Prospective and randomized clinical trial.

Participants

Fifty eyes of 50 patients with diagnosis of glaucoma that were candidate for AGV surgery were included.

Methods

In 25 eyes, conventional AGV surgery (group 1) and in 25 eyes AGV surgery with subconjunctival Bevacizumab (group 2) was performed by block randomization

Main Outcome Measures

The primary outcome measure was surgical success. Outcome measures were compared at postoperative month 3, 6 and 12.

Results

Mean age of patients was 58.76 ± 12.11 and 51.36 ± 15.44 years in group 1 and 2 respectively (P = 0.06). Mean intraocular pressure (IOP) at baseline was 24.88 ± 7.62 mmHg in group 1 and 27.52 ± 8.57 mmHg in group 2 which decreased to15.4 ± 4.4 mmHg in group 1 and 13.42 ± 2.9 mmHg in group 2 (P < 0.00) at last follow up. Surgical success was defined in two level: postoperative IOP ≤ 21 mmHg with at least 20% reduction in IOP (Criterion A), either with no medication (complete success) or with no more than two medications (qualified success) and criterion B with the same definition but the IOP ≤ 18 mmHg The cumulative success according to criterion A and B was 77.8%, 72.2% in group 1 and 89.5% in group 2, respectively, at the end of follow‐up.

Conclusions and Relevance

Subconjunctival injection of Bevacizumab adjunctive to AGV implantation leads to higher success rate compared with AGV alone in one year follow‐up.     

Ahmed青光眼阀植入联合视网膜光凝或冷凝治疗新生血管性青光眼

目的:探讨Ahmed青光眼阀植入联合视网膜光凝或冷凝术对新生血管性青光眼治疗的临床效果。方法:选取4a来住院的新生血管性青光眼56例58眼,其中视网膜中央静脉阻塞25例25眼,糖尿病性视网膜病变21例23眼,视网膜血管炎5例5眼,颈动脉狭窄4例4眼,视网膜分支静脉阻塞1例1眼,平均年龄50.6岁,均行Ahmed青光眼阀植入联合视网膜光凝或冷凝治疗,其中47眼于手术前后行全视网膜光凝,11眼于手术中联合周边视网膜冷凝术,平均随访18.0±6.2mo,观察手术前后视力和眼压的变化以及术后并发症的情况,结果进行统计学分析。结果:视力:术后43眼有不同程度地提高,15眼无变化,无视力下降者。眼压:随访6mo时眼压由术前49.56±8.25mmHg降至17.86±5.25mmHg,总成功率为85%;随访12mo时,眼压由术前50.25±7.18mmHg降至18.80±6.81mmHg,总成功率为78%;24mo以上随访19眼,眼压由术前51.05±8.10mmHg降至20.12±7.01mmHg,总成功率为74%,手术前后眼压比较差异有非常显著性。并发症主要有前房出血、前房延缓形成、引流管内口堵塞、引流盘纤维包裹,经术后处理均得到了恢复。结论:Ahmed青光眼阀植入联合视网膜光凝或冷凝是治疗新生血管性青光眼安全有效的方法之一。     

Clinical Outcomes of Ahmed Glaucoma Valve Implantation Using Tube Ligation and Removable External Stents

Purpose

To investigate the immediate and long-term outcomes of Ahmed glaucoma valve (AGV) implantation with silicone tube ligation and removable external stents.

Methods

This retrospective non-comparative study investigated the outcomes of AGV implantation with silicone tube ligation and removable external stents in 95 eyes (90 patients) with at least 12 months of postoperative follow-up. Qualified success was defined as an intraocular pressure (IOP) of ≤21 mmHg and ≥6 mmHg regardless of anti-glaucoma medication. Those who required additional glaucoma surgery, implant removal or who had phthisis bulbi were considered failures. Hypotony was defined as an IOP of <6 mmHg.

Results

Mean IOP reduced from 37.1±9.7 mmHg preoperatively to 15.2±5.6 mmHg at 12 months postoperatively (p<0.001). Qualified success was achieved in 84.2% at 1 year. Hypotony with an IOP of <6 mmHg was seen in 8.4% and an IOP of <5 mmHg in 3.2% on the first postoperative day. No case of hypotony required surgical intervention. Suprachoroidal hemorrhage did not occur in this study. When stents were removed on the first postoperative day because of an insufficient IOP decrease, the mean IOP decreased significantly from 42.0 mmHg to 14.1 mmHg (p<0.001) after 1 hour. The most common complication was hyphema, which occurred in 17.9%.

Conclusions

Hypotony-related early complications requiring surgical intervention were reduced by ligation and external stents in the tube. In addition, early postoperative high IOPs were managed by removing external stents. The described method can prevent postoperative hypotony after AGV implantation and showed long-term success rates comparable to those reported previously.     

Ahmed引流阀植入联合玻璃体腔注射Bevacizumab治疗NVG

目的：观察Ahmed引流阀植入联合玻璃体腔注射bevacizumab(贝伐珠单抗)治疗新生血管性青光眼(neovascular glaucoma,NVG)的疗效。

方法：对22例22眼新生血管性青光眼患者先进行玻璃体腔注射bevacizumab 0.1mL(2.5mg),待虹膜新生血管消退后行Ahmed青光眼阀门植入术。术后观察视力、眼压、虹膜新生血管消退情况、术中及术后并发症,随访6～36(平均24)mo。

结果：玻璃体腔注药后1wk内22眼虹膜新生血管均有不同程度消退,Ahmed引流阀植入术后随访22眼中仅有3眼联合使用1～3种抗青光眼药物,眼压控制在21mmHg之内,1眼因眼压失控而行睫状体光凝术(810激光),其余18眼均无需加用抗青光眼药物眼压控制在正常范围内,最后一次随访,平均眼压15.59±3.21mmHg,与术前平均眼压(45.36±8.13mmHg)相比,差异有统计学意义(P<0.05)。视力提高者9眼(41%),保持术前视力者13眼。全部病例在玻璃体腔注射bevacizumab及Ahmed引流阀植入术中术后均未观察到严重手术并发症。

结论：Ahmed引流阀植入联合玻璃体腔注射bevacizumab治疗NVG安全有效,手术成功率高,并发症少,有利于保护残留视功能。     

Clinical outcomes of the PAUL® glaucoma implant: One-year results

Background

To report one-year outcomes from a single-centre cohort undergoing PAUL® Glaucoma Implant (PGI) surgery.

Methods

Retrospective review of patients undergoing PGI surgery at the University Eye Hospital Bonn, Germany, from April 2021 to September 2021.

Results

Forty-five eyes of 41 patients were included. Qualified and complete success rates (95% CI) were 95.6% (88.9%–100%) and 73.3% (60%–86.7%) for Criterion A (IOP ≤ 21 mmHg), 84.4% (73.3%–93.3%) and 74.4% (51.1%–80.0%) for Criterion B (IOP ≤ 18 mmHg), 62.2% (48.9%–75.6%) and 46.7% (31.2%–62.2%) for Criterion C (IOP ≤ 15 mmHg) and 26.7% (13.3%–40.0%) and 22.2% (11.1%–33.3%) for Criterion D (IOP ≤ 12 mmHg), respectively. Mean IOP decreased from 26.1 mmHg (7–48 mmHg) to 12.0 mmHg (3–24 mmHg) (reduction of 48.83%) after 12 months with a reduction of IOP-lowering agents from 0.5 (0–3). One eye (2.2%) needed an injection of viscoelastic due to significant hypotony with AC shallowing, and four eyes (8.9%) developed choroidal detachments due to hypotony which resolved without further interventions after 6 weeks. Three patients (6.7%) developed tube exposure which required conjunctival revision with an additional pericardial patch graft. An intraluminal prolene stent was removed in 19 eyes (42.2%) after a mean time period of 8.4 months (2–12 m). Mean IOP before the removal was 21.9 mmHg (12–38 mmHg) and decreased to 11.3 mmHg (6–16 mmHg).

Conclusions

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy. An intraluminal prolene stent impedes hypotony in the early postoperative phase and enables further IOP lowering without additional interventions during the postoperative course.     

Evaluation of Ahmed glaucoma valve implantation through a needle-generated scleral tunnel in Mexican children with glaucoma

Purpose:

To evaluate the results and extrusion rates of the Ahmed glaucoma valve (AGV) implantation through a needle-generated scleral tunnel, without a tube-covering patch, in children.

Materials and Methods:

A retrospective review of the charts of 106 Mexican children implanted with 128 AGVs operated between 1994 and 2002, with the needle track technique, at our institution, with at least six months follow up was done. Main outcome measures were intraocular pressure (IOP) control, tube extrusions or exposure and other complications.

Results:

Kaplan-Meier analysis demonstrated a 96.9% survival rate at six months, 82.4% at one year, 78.7% at two years, 70% at three years and 41.6% at four years. Total success at the last follow-up (IOP between 6 and 21 mm Hg without medications) was achieved in 30 eyes (23.5%), 58 eyes (45.3%) had qualified success (only topical hypotensive drugs) and 40 eyes (31.3%) were failures. The mean pre- and post-operative IOP at the last follow up was 28.4 mmHg (SD 9.3) and 14.5 mmHg (SD 6.3), respectively. No tube extrusions or exposures were observed. Tube-related complications included five retractions, a lens touch and a transitory endothelial touch. The risk of failure increased if the eye had any complication or previous glaucoma surgeries.

Conclusion:

Medium-term IOP control in Mexican children with glaucoma can be achieved with AGV implantation using a needle-generated tunnel, without constructing a scleral flap or using a patch to cover the tube. There were no tube extrusions, nor any tube exposures with this technique.     

Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years

Purpose: To examine the rates of intermediate‐term intraocular pressure (IOP) control after trabeculectomy with adjunctive mitomycin C (MMC) and assess for associated complications. Methods: Medical records of patients undergoing primary trabeculectomy with MMC at Concord Repatriation Hospital, Sydney between January 1997 and December 2005 were reviewed. All eyes with a minimum of 2‐year follow up were included. Follow‐up data were collected in a standardized form on postoperative IOP, bleb‐related and other complications. Success was measured as IOP ≤ 18 mmHg and ≥6 mmHg (criteria 1) with (qualified success) or without (absolute success) the use of glaucoma medications. A secondary outcome measure was an IOP reduction of greater than 20% from baseline (criteria 2). Eyes with preoperative IOP of 18 mmHg or less were included, but also analysed separately to those eyes with preoperative IOP above 18 mmHg. Results: Sixty eyes from 42 patients were included in the study, with 3‐year follow up on 48 eyes. Mean preoperative IOP was 25.3 mmHg (range 8–45) and mean postoperative IOP was 14.0 mmHg at 1‐ and 2‐year follow up, and 14.7 mmHg at 3 years (ranges: 3–31, 4–30 and 8–45 mmHg respectively). Cumulative success for criteria 1 was 85.0% at 2 years and 83.3% at 3 years, and for criteria 2 it was 80.0% and 79.2%, respectively. The number of eyes on glaucoma medications was reduced from 51 preoperatively to 30 at 3 years. Complications were infrequent. There was one eye with a shallow anterior chamber beyond the immediate postoperative period. One eye required cataract surgery at 1‐year follow up. Subgroup analysis was performed using the first operated eye only, and results did not differ significantly from overall results. Conclusion: MMC‐augmented trabeculectomy can significantly reduce IOP in the short and intermediate term, with a favourable safety profile.     

YAG激光虹膜周切术治疗药物难控制性急性闭角型青光眼

目的:探讨YAG激光周边虹膜切除术在药物难控制急性闭角型青光眼治疗中的作用。方法:回顾分析我院住院患者共124例124眼,其中男51例,女73例,入院诊断符合急性闭角型青光眼发作期临床特征,且药物治疗24h后眼压仍>21mmHg的急性闭角型青光眼患者,其中控制眼压为21~35mmHg者51眼(41.1%),眼压36~50mmHg者37眼(29.8%),50mmHg以上者36眼(29.1%)。视力范围为光感~0.3。所有患者均在表面麻醉下行YAG激光周边虹膜切除术治疗,术后继续观察眼压、视力、前房深度变化,眼压控制稳定后分别进行小梁切除术、青光眼白内障联合人工晶状体植入术,或单纯白内障超声乳化吸出联合人工晶状体植入术。结果:患者124例124眼急性闭角性青光眼患者行YAG激光虹膜周切术后,第2d检测眼压≤21mmHg者28眼(22.6%),眼压为22~35mmHg者60眼(48.4%),眼压36~50mmHg者25眼(20.2%),眼压>50mmHg者11眼(8.9%);激光术后视力增加3行者33眼（26.6%）,2行者31眼(25.0%),视力增加1行者44眼(35.5%),视力不增加者16眼(12.9%);119眼前房深度增加(96.0%); YAG激光虹膜周切术后并发前房出血98眼(79.0%)。眼压控制稳定后分别进行小梁切除术37眼,青光眼白内障联合人工晶状体植入术43眼,白内障超声乳化吸出联合人工晶状体植入术44眼。观察随访3~9mo,眼压控制≤18mmHg者95眼,眼压≤25mmHg者24眼,眼压为26~35mmHg者5眼,未见前房积血、黄斑囊样水肿等并发症。结论:YAG激光虹膜周切术在药物难控制性急性闭角型青光眼治疗中能明显降低眼压,为各种青光眼手术的治疗提供安全可靠的条件,有助于视功能保护和恢复,提高疗效。     

内窥镜下睫状体光凝治疗儿童青光眼的长期临床观察

目的评价内窥镜下睫状体光凝(ECP)治疗儿童青光眼的长期疗效和安全性。方法回顾性系列病例研究。收集2013年8月至2020年5月在首都医科大学附属北京同仁医院眼科中心接受内窥镜下睫状体光凝的儿童青光眼患者。观察指标包括第一次ECP手术时的年龄、青光眼类型、术前与术后最后一次随访时的视力及眼压等。采用配对t检验比较术前及术后末次随访眼压和视力。采用独立样本t检验和卡方检验比较成功组及失败组的各项临床特征。结果 22例(27眼)儿童青光眼患者纳入本研究。其中先天性白内障术后12眼,玻璃体切除视网膜复位联合硅油填充术后10眼,外伤性白内障术后2眼,先天性青光眼3眼。随访时间为6个月至6年(中位数:5年)。术前眼压为37.8±8.1 mmHg,ECP平均次数为1.2±0.6次,术后末次随访眼压为22.6±9.8 mmHg,术后眼压下降幅度约40%。末次随访时,19眼眼压控制,7眼眼压失控,1眼眼球萎缩。行1次及以上ECP手术的1年,3年,5年及6年的累积成功率分别为84.4%,71.7%,71.7%,53.8%。手术成功组首次ECP范围(均值:287^O)比失败组大(均值:223^O)。结论 ECP对治疗儿童青光眼,尤其是难治性继发性青光眼是有效的。术后眼压在药物辅助下可以长期稳定。对儿童青光眼长期乃至终身眼压随访是至关重要的。     

Ahmed青光眼阀植入治疗难治性青光眼

目的：探讨Ahmed青光眼阀植入治疗难治性青光眼的临床疗效。 方法：回顾性研究我院Ahmed青光眼阀植入术治疗21例21眼难治性青光眼的临床疗效并进行总结分析。 结果：术前平均眼压为44.6±7.2mmHg,术后6mo末次随访平均眼压15.4±5.3mmHg;视力提高4眼,无改变14眼,降低3眼;手术并发症主要包括术后前房形成迟缓2眼、持续高眼压1眼、引流管暴露1眼、角膜失代偿1眼、引流盘纤维包裹3眼;手术成功率为86％。 结论：Ahmed青光眼阀植入术是治疗难治性青光眼有效和安全的方法。     

联合手术治疗青光眼合并白内障的临床观察

目的:探讨治疗青光眼合并白内障的手术方法及临床效果。方法:对45例45眼青光眼合并白内障患者施行白内障超声乳化及人工晶状体植入联合隧道内小梁切除术。结果:术前视力<0.1者32眼,0.1～0.3者13眼。术后视力<0.1者6眼(13%),0.1～0.5者22眼(49%),>0.5者17眼(38%)。术前眼压26～60mmHg,术后42例眼压降至正常范围,3例经局部按摩、滴药后降至正常,平均眼压12.78±2.70mmHg。随访6～12mo,无1例眼压再升高。3例视力下降,经戴镜矫正视力提高。并发症主要是角膜水肿和虹膜炎症反应。结论:白内障超声乳化人工晶状体植入联合隧道内小梁切除术是治疗青光眼合并白内障的理想方法。     

白内障超声乳化术治疗急性闭角型青光眼合并白内障

了解白内障超声乳化术治疗急性闭角型青光眼合并白内障的有效性。 方法:对2006-03-01/2010-10-31收治的急性闭角型青光眼合并白内障患者47例51眼,眼压稳定后行超声乳化联合人工晶状体植入术,术后均随访1~3a。 结果:术后47例51眼中44例48眼眼压下降,术前眼压22.98±3.22mmHg,术后眼压13.24±3.17mmHg(P<005),45例49眼视力较术前明显提高(P<0.05)。47例51眼术后前房深度加深,由术前1.542±0.314mm转为术后3.157±0.243mm(P<0.05)。 结论:白内障超声乳化术可以使急性闭角型青光眼前房加深,不同程度地开放已关闭的房角,改善周边窄房角的解剖状态,降低瞳孔阻滞后周边前房关闭的可能性,可以使升高的眼压下降,提高视力,是闭角型青光眼合并白内障患者安全有效的治疗途径。     

260例青光眼白内障联合手术临床分析

目的：分析评价青光眼白内障联合手术的疗效。方法：对２６０例（２７９眼）行青光眼白内障联合手术的病例作回顾性分析,并将病人分为３组。Ⅰ组：白内障囊外摘除联合小梁切除术;Ⅱ组：白内障囊外摘除、人工晶体植入联合小梁切除术;Ⅲ组：超声乳化白内障吸出、人工晶体植入联合小梁切除术;并分析比较３组的术后视力、眼压和并发症。结果：３组病例术后视力≥０．３者分别为１６．３％、３２．４％和４３．５％,术后视力改善率分     

Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma

Background: To report the outcome of intravitreal Bevacizumab followed by Ahmed valve implantation in the management of neovascular glaucoma in a patient group with extended follow-up. Methods: The records of 16 patients (18 eyes) with neovascular glaucoma refractory to medical therapy who presented to a single surgeon between 2006–2008 were reviewed. Patients received pan-retinal photocoagulation and then intravitreal Bevacizumab followed by Ahmed valve implantation. The main outcome measures were: control of IOP (with or without additional medication), visual acuity (VA) and failure (IOP >21 mmHg or <6 mmHg, reoperation for glaucoma, or loss of light perception). Results: Pre-operatively, all patients received pan-retinal photocoagulation followed by IVB at a mean of 15.9 (range 4–60) days prior to AGV. The mean pre-operative IOP was 37.1 mmHg (±13.4) on 3.2 (±0.87) medications. Of the 18 eyes, 14 eyes (78%) were treated with AGV alone and 4 eyes (22%) with AGV combined with cataract extraction. Sixteen eyes (89%) received mitomycin C treatment intraoperatively. Post-operatively, the mean follow-up period was 63 months (24–84). At final follow-up, the success rate was 50% (33.3% complete, 16.7% qualified) with a mean IOP of 18.1 mmHg (±9.5) on a mean number of 1.5 (±1.6) medications. The failure rate was 50%, with five eyes (27.8%) not meeting the IOP criteria for success (of these, three eyes required additional surgery to lower the IOP) and five eyes (22.2%) lost light perception. Conclusion: Intravitreal Bevacizumab followed by AGV offers long-term control of IOP without additional surgical intervention in the majority of cases.     

AGV植入联合MMC及视网膜光凝治疗NVG

目的：观察 Ahmed青光眼阀(Ahmed glaucoma valve,AGV)植入术中应用丝裂霉素C(MMC)联合视网膜光凝治疗新生血管性青光眼(neovascular glaucoma,NVG)的临床疗效。

方法：回顾性分析行AGV植入术中应用MMC联合视网膜光凝术治疗的41 例41眼NVG患者临床资料,观察患者眼压变化、视力变化、手术成功率及并发症情况。

结果：患者术前平均眼压49.8±4.3mmHg,术后1,3,6,12mo分别为18.30±4.50,19.40±5.37,18.45±4.60,17.85±3.66mmHg。末次随访平均眼压20.25±4.2mmHg,与术前眼压相比差异均具有统计学意义(P<0.05)。随访6～24mo,手术成功率为93% ,其中完全成功36眼(88%),部分成功2眼(5%),失败3眼(7%)。手术前后视力差异无统计学意义(P>0.05)。术后常见并发症为术后早期低眼压4眼(10%); 术后浅前房1眼(2%); 前房少量出血3眼(7%); 引流管内口阻塞1眼(2%)。

结论：AGV植入术中应用MMC联合视网膜光凝治疗NVG临床疗效显著,可以有效降低NVG患者的眼压。     

抗VEGF联合Ahmed引流阀治疗NVG术中是否联合超乳的对比观察

目的：观察抗VEGF联合Ahmed引流阀植入术中白内障超声乳化与非超乳治疗合并白内障的新生血管性青光眼(NVG)的疗效。

方法：回顾分析我院诊断为NVG合并白内障的患者47例47眼,术前均行抗VEGF玻璃体积内注射,其中19眼行白内障超声乳化吸除术联合Ahmed引流阀植入术(联合组),28眼行单纯Ahmed引流阀植入术(单阀组),术后观察视力、眼压和用药情况,并随访6mo以上。

结果：NVG患者47眼中,术后各时间点眼压均较术前显著降低(P<0.05)。随访至6mo时,联合组患者视力提高者10 眼(53%),不变者8眼(42%),降低者1眼(5%); 手术完全成功率为84%(16/19),条件成功率 11%(2/19),失败5%(1/19); 单阀组患者视力提高者11眼(39%),不变者17眼(61%),降低者0例,手术完全成功率为61%(17/28),条件成功率 25%(7/28),失败14%(4/28)。

结论：抗VEGF和单纯Ahmed引流阀植入术联合白内障超声乳化摘除手术既能有效控制术后眼压,又尽可能提高患者视力,减少术后青光眼药物使用量,便于随诊眼底,是治疗NVG的有效方法。     

Ex-press青光眼引流器植入术治疗难治性青光眼的疗效及并发症

目的：探讨Ex-press青光眼引流器植入术治疗难治性青光眼的临床疗效及并发症。
　　方法：随机选取本院2013-02/2014-08收治行 Ex-press青光眼引流器植入术治疗的难治性青光眼53例56眼,男39例41眼,女14例15眼,平均年龄52.63±10.58岁;新生血管性青光眼25例26眼,滤过手术失败后青光眼16例18眼,玻璃体切除术后继发青光眼6例6眼以及复杂眼外伤后青光眼6例6眼。观察术后1、12 lo视力、眼压、前房深度、角膜内皮细胞密度及并发症等情况,并与术前进行分析比较。
　　结果：术后12lo,完全成功率为62%(35眼),部分成功率为14%(8眼),总成功率为77%。其中新生血管性青光眼有效率为85%,滤过手术失败后青光眼有效率为56%,复杂眼外伤后青光眼100%,玻璃体切除术后青光眼83%。术后1 lo视力较术前提高者28眼(50%),视力不变18眼(32%),视力降低10眼(18%)。术后12lo视力较术前提高者19眼(34%),视力不变18眼(32%),视力降低19眼(34%)。术前平均眼压29.58±8.66llHg,术后1lo平均眼压12.75±5.66llHg,与术前比较差异有统计学意义(P<0.05),其中56例患眼眼压均表现为降低(100%)。术后12lo 眼压为9.8~28.4(平均15.42±4.09)llHg,与术前比较差异有统计学意义(P<0.05),其中眼压较术前增高者2眼,眼压不变0眼,眼压降低54眼(96%)。术后1、12lo 内皮细胞计数分别为1958.22±168.30、1793.99±201.55个/ll2,与术前的2113.47±80.56个/ll2比较,差异有统计学意义(P<0.01)。术后总并发症发生率为29%,其中术后早期发生浅前房低眼压4眼,暂时性高眼压3眼,引流管阻塞5眼,前房出血3眼。后期并发症有局部隆起的包裹的囊状泡1眼。
　　结论：Ex-press青光眼引流器植入术治疗难治性青光眼,虽然存在一定的术后并发症,但仍可取得较好的临床疗效,是目前治疗难治性青光眼的有效方法。